AGL 2043 is a cell-permeable, tricyclic quinoxaline compound that acts as a potent, selective, ATP-competitive, and reversible inhibitor of type III receptor tyrosine kinases PDGFR (IC₅₀ = 800 nM in 3T3 cells; 90 nM against purified PDGFβ-receptor), Flt-3/Flk-2 (Flt3), and c-Kit (Kit) (IC₅₀ ~1-3 μM).Weakly inhibits PKA, EGFR, IGF-1R, VEGFR, and Src kinases (IC₅₀ > 30 μM). Potently inhibits smooth muscle cell proliferation and balloon-induced stenosis in porcine heart.

A cell permeable compound that acts as a potent inhibitor of type III receptor tyrosine kinases

Store at 4° C

Solid

type III receptor tyrosine kinases PDGFR: IC₅₀ = 800 nM (3T3 cells); purified PDGFβ-receptor: IC₅₀ = 90 nM; Kit: IC₅₀ = 1-3 µM; Src kinases: IC₅₀ = >30 µM

Soluble in DMSO (10 mg/ml).

9817165